ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial ...
ImmunityBio’s IBRX QUILT-2.005 trial tops enrollment forecasts; BLA filing targeted by year-end after positive ANKTIVA+BCG ...
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc.
The QUILT-2.005 trial is a randomized registrational study designed to evaluate the effectiveness of ANKTIVA® combined with BCG in BCG-naïve patients. As of January 2026, enrollment has surpassed 85%, ...
InvestorsHub on MSN
Theralase and Ferring ink deal for new bladder cancer study
Theralase Technologies (USOTC:TLTFF) signed a clinical development agreement with Ferring Pharmaceuticals, a top name in ...
Bacillus Calmette-Guérin (BCG) vaccine is the live attenuated vaccine form of Mycobacterium bovis used to prevent tuberculosis and other mycobacterial infections. Now, using zebrafish “avatars,” a ...
By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.
The principal investigator of the study leading to approval said this new immunotherapy could be a "game changer" in bladder cancer. FDA last night approved nogapendekin alfa inbakicept-pmln (NAI) ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Discussion on current and future treatments for BCG-unresponsive HR NMIBC presented at ESMO 2023. This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD. Daneshmand ...
Despite the success of the PD-1 inhibitor sasanlimab in this setting, adding the PDL-1 inhibitor atezolizumab to intravesical BCG does not improve EFS in naïve patients with high-risk NMIBC, according ...
Intravesical bacillus Calmette-Guérin (BCG) with and without isoniazid (INH) is associated with outcomes superior to those intravesical epirubicin in patients with intermediate- and high-risk Ta and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback